Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Karessa Pharma Holding AB announces today that the first patient is dosed in the company's clinical study with K-03 Vardenafil buccal film

Today, the dosing of healthy volunteers begins in Karessa's clinical trial K-03/1 buccal film. The study will last for five weeks and is planned to be completed on 15th of December 2017.The study is a Phase I, open, randomized, single-center study on healthy male subjects in order to determine the PK profile in the body (pharmacokinetic profile) of Vardenafil given as K-03/1 buccal film. The study consists of comparing the PK profile of four different variants of K-03/1 buccal film. Except for the evaluating of PK profile, the safety and tolerability of Karessa's K-03/1 buccal film will

Stillfront Group AB: Stillfront Interim Report January-September 2017

Interim Report January-September 2017 Press Release November 14, 2017   STILLFRONT GROUP AB (PUBL) The interim period January - September 2017 · Net revenues amounted to 112.7 MSEK (corresponding period 2016: 70.3 MSEK), which is an increase of 60% compared to the corresponding period 2016. Total operating revenues amounted to 139.2 MSEK (87.0). · EBITDA amounted to 36.9 MSEK compared to 27.5 during the corresponding period 2016. EBITDA has increased due to a written-off debt and has been charged with acquisition costs, costs pertaining to improved IT infrastructure at

OmniCar holding AB announces new board member

We are very pleased to announce that Andreas Klainguti has accepted to join the board of directors of OmniCar Holding AB. Andreas Klainguti will be replacing Mikkel Lippmann, COO at Omnicar Holding AB.Andreas Klainguti has worked for more than 25 years in Investment Banking for Merrill Lynch, Standard Chartered Bank and Citigroup in Zurich, London and Hong Kong. As a Manging Director he was Head of Derivatives EMEA and Asia, Head of Global Equity Trading and Head of Global Strategic Risk. Since moving to Denmark in 2013 he has been advising various Banks and Hedge Funds on Business set up,

Etrion Releases Third Quarter 2017 Results

November 14, 2017, Miami, Florida, United States – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, today released its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three and nine months ended September 30, 2017.  Etrion Corporation delivered strong project-level results in the third quarter of 2017 driven by the Japanese assets. Higher installed capacity and electricity production resulted in a significant increase in revenue and project-level EBITDA compared

Odfjell SE signs Framework Agreement with Sinochem Shipping Singapore Pte. Ltd to take 4 stainless steel vessels on long-term bareboat charters and to form a pool of 8 chemical tankers

Odfjell SE ("Odfjell") has signed a Framework Agreement with Sinochem Shipping Singapore Pte. Ltd ("Sinochem") whereby Odfjell will take 4 of a total newbuilding order of 8 x 40,900 dwt chemical tankers on long-term bareboat charters. The bareboat charters include purchase options at the end of the charter period. Sinochem will continue to own 4 vessels, which together with the 4 bareboat vessels will form a pool of 8 x 40,900 dwt sophisticated chemical tankers. The pool will be managed by Odfjell SE and the vessels will trade as part of the Odfjell Tankers fleet. The series of

New Swedish study results at SABCS show DiviTum® blood test reduces waiting times for evaluating breast cancer treatment

Uppsala, Sweden, November 14, 2017. Results from a study of 142 women with newly diagnosed metastatic breast cancer will be presented by researchers from Lund University at the world’s biggest breast cancer conference in San Antonio, USA. The study demonstrates that the DiviTum® blood-based biomarker can provide more accurate prognosis than today’s standard methods.With imaging methods used for evaluating the effect of treatment, it takes about three months to evaluate whether the given therapy is effective or not. The new study demonstrates that DiviTum® accurately can predict outcome (

BONESUPPORT™ - CERAMENT® G’s POTENTIAL TO PREVENT AND MANAGE BIOFILM-RELATED BONE INFECTIONS HIGHLIGHTED IN NEW HIGH-PROFILE PUBLICATION

Lund, Sweden, 08.00 CET, 14 November 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform announces the publication of a paper highlighting the anti-biofilm activity of CERAMENT® G in vitro - Colloids and Surfaces B: Biointerfaces 161 (2018) 252–260. Implant-related bone infections caused by microorganisms that grow in biofilms are extremely difficult to treat and cause persistent and recurring infections. The use of

BerGenBio Presents BGB324 and KEYTRUDA® (pembrolizumab) Clinical Trial at the 2017 San Antonio Breast Cancer Symposium

Bergen, Norway, 14 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, is pleased to announce that the Company will present its recently initiated Phase II clinical trial investigating BGB324 in combination with the Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with triple negative breast cancer (TNBC) at the 2017 San Antonio Breast Cancer Symposium in San Antonio, USA (5-9 Dec

New Swedish study results at SABCS show DiviTum ® blood test reduces waiting times for evaluating breast cancer treatment

Uppsala, Sweden, November 14, 2017. Results from a study of 142 women with newly diagnosed metastatic breast cancer will be presented by researchers from Lund University at the world’s biggest breast cancer conference in San Antonio, USA. The study demonstrates that the DiviTum® blood-based biomarker can provide more accurate prognosis than today’s standard methods.With imaging methods used for evaluating the effect of treatment, it takes about three months to evaluate whether the given therapy is effective or not. The new study demonstrates that DiviTum® accurately can predict outcome (

Elos Medtech commits to the global orthopaedic market

Orthopaedics is a strategically important business segment for Elos Medtech and today we announce our commitment to focus on and grow this market. We will dedicate resources and develop a strong cross-site platform to further build our competence and capacity in support of our global customers. Elos Medtech announces that Jodie Gilmore, Managing Director Elos Medtech Onyx, will take up a new role as Orthopaedic Business Director and lead our global orthopaedic strategy as we continue our journey focusing entirely on the medical device industry. “Elos Medtech is excited to highlight

Hansa Medical Interim report July – September 2017

July-September in brief ›› Combined data from three independent clinical Phase II studies with Hansa Medical’s lead candidate IdeS was published in The New England Journal of Medicine 2017;377:442-53, August 3, 2017 issue. Data from these studies show that IdeS effectively reduces HLA antibodies and enables patients with very poor prognosis, who are unlikely to find a kidney donor, to be transplanted. Importantly, patients were doing well with good kidney function at last follow up. ›› Patient enrollment on target to have all patients recruited and treated by the end of 2017 in two

Hexagon Showcases Digital, Safe and Connected Solutions at Smart City Expo World Congress

Hexagon AB, a leading global provider of information technology solutions, will showcase its solutions for digital, safe and connected smart cities in Barcelona, Spain at Smart City Expo World Congress , the leading international event for smart cities.Driven by disruptive innovation, Hexagon’s information technology portfolio empowers customers with integrated data feeds and seamless workflows to create smart ecosystems, which Hexagon calls Smart X. From smart cities, smart power plants, and smart factories, to smart mines and smart farms,

OX2 sells 21.6 MW wind farm in Sweden to Fontavis

Fontavis, a Swiss asset manager within the energy and infrastructure field, has signed a purchase agreement with OX2 for six turbines at Stigshöjden with a total output of 21.6 MW.OX2 began work on the Stigshöjden wind farm, which is in Västernorrland, 35 km southwest of Örnsköldsvik, earlier this year. OX2 will also manage the park for Fontavis when the wind farm is completed in the autumn of 2019. Its expected average production is approximately 62 GWh per year. “Stigshöjden and the collaboration with OX2 is an ideal starting position to leverage Fontavis’ activities in the Nordics”

Rottneros invests another 117 SEKm within the framework of Agenda 500

As a next step in the capacity development of Rottneros Mill, Rottneros’ Board has granted further investments in the CTMP line. The investment, CTMP Step 2, increases capacity by approximately 18,000 tonnes per year and is expected to be operational in the fall of 2018. The investment follows the strategic development plan Agenda 500, where a first capacity-enhancing investment in the CTMP line was made in 2016. Within Agenda 500, Rottneros Mill has put into operation a bio mass boiler in the third quarter of 2017 that replaces an oil-based boiler and made the mill practically fossil-free.

Interim report January - September 2017

Third quarter 2017 ·Revenues amounted to SEK 180.7 (127.2) million, an increase by 42 % compared to the same period last year. ·Operating profit amounted to SEK 52.9 (54.6) million, a decrease by 3 %. ·Profit before tax amounted to SEK 52.6 (54.6) million, and profit after tax amounted to SEK 40.6 (42.3) million. ·Cash flow from operating activities amounted to SEK 70.3 (102.7) million, and cash flow from investing activities amounted to SEK -79.2 (-30.8) million. ·By the end of the period cash and short term placements amounted to SEK 244.3 (215.1)

KID ASA – THIRD QUARTER 2017 RESULTS

Lier, 14 November 2017: The board of directors of Kid ASA has approved the financial report for the third quarter of 2017. Q3 HIGHLIGHTS (Figures from corresponding period the previous year in brackets) · Revenues of MNOK 343.8 (MNOK 314.1) in Q3 2017, an increase of 9.5% (9.2%). For the first three quarters of 2017, revenues amounted to MNOK 876.1 (MNOK 810.1), up 8.2% (8.2%) from 2016. The number of ordinary shopping days in the third quarter was 79 (79), and for the three first quarters 227 (228). · Like-for-like sales increased by 5.1% (6.7%) in the quarter and 5.1% (4.3%)

REDUCED SALES DUE TO FEWER CUSTOMER PROJECTS

Sales dropped during the third quarter due to the company’s having won fewer customer projects because of tough competition in the market for capacitive sensors. The lower level of sales resulted in an operating loss. The technology shift from capacitive sensors to new sensor technologies is opening up new opportunities. Precise Biometrics is involved in several projects involving ultrasound and optical sensors, as well as biometric payment cards. THIRD QUARTER   · Net sales for the remaining operation totaled SEK 10.1 (23.0) million. · The operating profit/loss for the

Schörling & Partners AB announces an unconditional cash offer of SEK 569 per share to the shareholders of Melker Schörling AB

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States of America, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law.The Schörling

Ratos: Interim report January-September 2017

Press release 14 November 2017 This information is information that Ratos AB is obliged to make public pursuant to the EU Market Abuse Regulation.The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 14 November 2017. Development in company portfolio · Sales unchanged · EBITA amounted to SEK 1,006m (938), +7% · Adjusted EBITA totalled SEK 1,045m (1,124), -7% Acquisitions and divestments · Divestment of Nebula completed in the third quarter, exit gain SEK 515m · Divestment of Serena Properties

Outokumpu changes its segment reporting: Ferrochrome to be reported as a new reportable segment as of January 1, 2018

Outokumpu OyjStock exchange releaseNovember 14, 2017 at 9.00 am EET   Outokumpu will change its segment structure as of January 1, 2018 by separating Ferrochrome operations from Business Area Europe as a new reportable segment. In the new structure, Outokumpu will have four reportable segments – Europe, the Americas, Long Products and Ferrochrome. Outokumpu’s financial reporting will be changed accordingly as of the first-quarter interim statement 2018. Ferrochrome operations are an integral part of Outokumpu’s business, and will be managed separately. Coupled with Kemi mine,

DP World Yarimca is upgrading two Konecranes RTGs to remote operation

In a move that shows great confidence in the future viability of Konecranes’ container crane technology, DP World, the global trade enabler, is upgrading two of its Konecranes Rubber Tired Gantry (RTG) cranes to test the capabilities of remote operation. This will take place at DP World’s Yarimca container terminal in Turkey, which operates a fleet of 18 Konecranes RTGs. DP World is exploring the possibilities of better productivity through remote container crane operation. The DP World Yarimca container terminal, one of the largest container terminals in Turkey with 1.3M TEU capacity,

SimCorp grows revenue by 10% in the first nine months of 2017 and adds three new clients in Q3

In the first three quarters of 2017, SimCorp generated revenue of EUR 229.2m, an increase of 10.4% (10.9% measured in local currencies) compared with restated* figures for the first nine months last year. EBIT for the nine months was EUR 43.0m compared with EUR 43.3m in restated 2016 figures, a decrease of 0.5%. Currency fluctuations impacted EBIT positively by EUR 0.8m. EBIT margin was 18.8% (18.3% measured in local currencies) compared with 20.8% in the first nine months of 2016 (restated). The revenue mix for the first nine months of the year has been skewed towards Professional

Actic Interim Report - Investments in our offer for stabilized customer base

In today's nine-momth report, Actic Group reported growth of 11 percent to SEK 652 (586) million, primarily driven by acquisitions. Organic growth was 4 percentage points, and the elements behind are intensified focus on add-on services and new establishments. At the same time, average earnings per member increased by 10 percent to SEK 336 (305) per month, due to strong development for the PT business. During the year, five new facilities were opened and twelve clubs were acquired, whereof nine will be consolidated from 1 December."In order to stabilize and grow the customer base, we

CXENSE ASA ANNOUNCES THIRD QUARTER RESULTS

OSLO, NORWAY - NOVEMBER 14, 2017 - CXENSE ASA TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDING 30 SEPTEMBER 2017. Highlights: Strategic change to focus on Data Management and Personalization* New CEO in place to execute strategy* Sale of non-core assets progressing well Growth in core segments of Data Management and Personalization* 15% YoY and 5.3% sequentially* Sales and churn improvement from Q2, but behind targets* 26 new customer contracts On track to reach post restructuring target EBITDA for Q1 2018 of USD -0.5 million* 83% of OPEX reduction

There are no items matching the current filter
There are no more items matching the current filter
Back to top